Biomarin Pharmaceutical Inc (BMRN) · Aug 6, 2026 · Company update

Revenue surged with Amicus; guidance moved higher despite flat adjusted EPS

Revenue surged with Amicus; guidance moved higher despite flat adjusted EPS

Revenue materially beat the standing expectation, while adjusted EPS essentially met it. Second-quarter revenue was $990 million versus a published consensus near $834 million, but the comparison is distorted by the April 27 Amicus acquisition, which added GALAFOLD and POMBILITI + OPFOLDA revenue. Non-GAAP diluted EPS was $1.20 versus consensus near $1.21, making the earnings result broadly in line rather than a beat.

MetricQ2 2026Q2 2025Change / expectation
Total revenue$990M$825M+20%; consensus approximately $834M
VOXZOGO revenue$253M$221M+14%
Non-GAAP diluted EPS$1.20$1.44-17%; consensus approximately $1.21
GAAP diluted EPS$0.23$1.23-81%
Non-GAAP operating margin36.4%39.9%Down 3.5 points
Operating cash flow, six months$389M$360MUp $29M

The underlying commercial trends were solid, but not uniformly strong. VOXZOGO grew 14% and patient counts rose more than 20% year over year, prompting a higher full-year sales range. PALYNZIQ grew 27%, while the newly acquired products supplied incremental scale. Against that, VIMIZIM fell 10% and ALDURAZYME fell 21% because of order timing, so part of the portfolio weakness may reverse but is still a drag in the reported quarter. (Product revenue table; Financial Highlights)

Management raised the pieces that matter most for the near-term outlook. Full-year revenue guidance moved from $3.825-$3.925 billion to $3.875-$3.925 billion, VOXZOGO guidance rose from $975 million-$1.025 billion to $1.0-$1.05 billion, and non-GAAP EPS guidance increased from $4.85-$5.05 to $4.90-$5.10. Metabolic Conditions and Other Revenues guidance was unchanged, so the upgrade is primarily a VOXZOGO and execution signal rather than a broad-based reset. (2026 Guidance table)

Profitability is the main offset to the strong revenue headline. Non-GAAP income fell to $236 million from $282 million and operating margin declined to 36.4% from 39.9%, reflecting Amicus-related interest expense, higher commercial spending, R&D costs, and integration charges. GAAP results were much weaker, with $45 million of net income versus $241 million, but the decline is heavily affected by acquisition amortization, inventory step-up, and transaction costs. (Non-GAAP reconciliation; Income Statement)

The filing improves the growth outlook but leaves a heavier balance-sheet burden. BioMarin financed the Amicus purchase with $3.65 billion of borrowings, ended June with $4.19 billion of debt and $874 million of cash, and still targets gross leverage below 2.5 times by mid-2027. Operating cash flow remained positive, but the acquisition consumed $5.07 billion of cash and the company expects roughly $200 million of annual financing interest. The net read is modestly positive versus expectations: a clear revenue and guidance win, largely offset by in-line adjusted earnings and materially higher leverage. (Balance Sheet; Cash Flow statement; Acquisition and leverage commentary)

Original filing on SEC EDGAR

More Biomarin Pharmaceutical Inc news

Revenue surged with Amicus; guidance moved higher despite flat adjusted EPS | BMRN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.